What Is Moving National HealthCare Stock Right Now?

National HealthCare (NHC) has drawn investor attention recently as the stock price and valuation metrics have shifted. This is prompting a closer look at how its current market pricing compares with reported fundamentals.

Recent trading in National HealthCare shows strong momentum, with a 30 day share price return of 6.07%, a 90 day share price return of 25.15%, and a 1 year total shareholder return of 88.49%, supporting a much stronger multi year total shareholder return profile.

If this kind of sustained move has you looking beyond a single stock, it could be a good moment to see what else is gaining traction through 39 healthcare AI stocks

With National HealthCare trading around $201.53 and an intrinsic value estimate that appears considerably higher on some models, the key question is simple: is the stock still undervalued, or is the market already pricing in future growth potential?

Price-to-Earnings of 25.5x: Is it justified?

On simple valuation measures, National HealthCare currently trades on a P/E of 25.5x. At a $201.53 share price, this points to a richer valuation than many peers.

The P/E ratio compares the company’s share price with its earnings per share and is a common way investors gauge how much they are paying for each dollar of profit. For a healthcare services business like National HealthCare, this can reflect expectations around the stability of earnings, potential for further profit growth, and the perceived quality of its operations.

Here, the signals are mixed. The SWS DCF model suggests the stock is trading below an estimated future cash flow value of $636.06, with the shares said to be 68.3% below that fair value estimate. At the same time, earnings growth over the past year of 14.6% is higher than the company’s 5 year average of 1.4% per year, and margins have edged higher, with net profit margins at 8.1% compared with 7.9% last year. These data points sit alongside an 11.5% return on equity, which is described as low, and a value score of 2 out of 6.

Against that backdrop, the 25.5x P/E looks full compared with both the broader US Healthcare industry P/E of 23.6x and a peer average P/E of 22.6x. The market is therefore attaching a premium to National HealthCare relative to these groups. This implies investors are paying a higher price for each dollar of current earnings than for many other healthcare stocks, even though recent earnings growth did not exceed the wider Healthcare industry figure of 16%.

Result: Price-to-Earnings of 25.5x (OVERVALUED).

However, National HealthCare still faces risks, including a relatively low value score of 2 out of 6 and a P/E premium that could compress if investor sentiment cools.

Another View on National HealthCare’s Valuation

The P/E premium suggests National HealthCare looks expensive, but the SWS DCF model points in the opposite direction. On that view, the stock price of $201.53 sits well below an estimated future cash flow value of $636.06, indicating a large potential undervaluation. Which signal should carry more weight for you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out National HealthCare for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 43 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on National HealthCare split between potential upside and clear risks, it makes sense to look at the data directly and decide quickly where you stand based on the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond National HealthCare?

If you are assessing National HealthCare, it can pay to line it up against other opportunities using the Simply Wall St screener and let the numbers guide you.

• Spot potential value opportunities early by checking stocks that stand out on fundamentals through the screener containing 19 high quality undiscovered gems.
• Prioritize resilience in your portfolio by filtering for companies with healthy balance sheets using the solid balance sheet and fundamentals stocks screener (48 results).
• Target income-focused opportunities by reviewing companies with higher yields and sturdier payouts via the 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.